ACC 2022 Highlights Podcast

In this episode (18:41 min), Medicom’s correspondent covers 6 presentations from the American College of Cardiology (ACC.22) which was held virtually and in person in Washington DC, USA this year, between the 2- 4 April 2022.

1. PACMAN-AMI’s alirocumab eats coronary plaques
   Adding the PCSK9 inhibitor alirocumab to high-intensity statin therapy shortly after an acute myocardial infarction (MI) promoted coronary plaque regression better than statin therapy alone, based on serial intracoronary imaging performed in the PACMAN-AMI trial.


2. 1-year CLASP TR data support tricuspid regurgitation repair
   Transcatheter valve repair with the PASCAL system provided further validation for transcatheter edge-to-edge repair. The prospective, multicentre CLASP TR study reported significant reductions in tricuspid regurgitation (TR) and improved quality of life (QoL) at 1 year.


3. DIAMOND trial: Patiromer scratches hyperkalaemia
   Heart failure with reduced ejection fraction (HFrEF) patients taking renin-angiotensin-aldosterone system inhibitors (RAASi) had significantly lower serum potassium levels when adding the potassium-binding agent patiromer to their regimen compared with placebo.


4. Dietary intervention… from your supermarket?
   The potential of dietary interventions in supermarkets in improving nutrition education was demonstrated by the positive findings from the Supermarket and Web-based Intervention Targeting Nutrition (SuperWIN) Trial presented at the ACC Scientific Sessions.


5. Treat chronic mild hypertension during pregnancy? Yes!
   New research from the randomised CHAP trial showed that aggressively targeting blood pressure in pregnant women with mild chronic hypertension to be <140/90 mmHg provided better pregnancy outcomes, with no consequent harm to either mothers or babies. The results were presented during the late-breaking clinical trial session of the American College of Cardiology and published simultaneously in the New England Journal of Medicine.


6. Sotagliflozin SCORED MACE benefit
   New analyses of the SCORED trial revealed that SGLT1/2 inhibitor sotagliflozin provides up to 23% risk reduction of major cardiovascular adverse events (MACE) in patients with type 2 diabetes, chronic kidney disease, and at high risk for cardiovascular disease.

Enjoy listening!

© 2023 The Author(s). Published by Medicom Medical Publishers.
User license: Creative Commons Attribution – NonCommercial (CC BY-NC 4.0)

Posted on 20 April, 202223 May, 2022